• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Abraxane (paclitaxel protein-bound particles for injectable suspension)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Abraxane (paclitaxel protein-bound particles for injectable suspension)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Abraxane (paclitaxel protein-bound particles for injectable suspension) is an intravenous nanoparticle, albumin-bound formulation of paclitaxel, a cancer chemotherapy, that is protein-stable and Cremophor-free. It was designed to deliver a greater amount of chemotherapy to cancer cells with fewer side effects.

    Abraxane is specifically indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

    Abraxane is supplied as a solution for intravenous injection. The recommended dose is 100 mg/m2 administered as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of each 21-day cycle. The recommended dose of carboplatin is AUC = 6 mg min/mL on Day 1 only of each 21-day cycle, beginning immediately after the completion of Abraxane administration.

    Clinical Results

    FDA Approval
    The FDA approval of Abraxane for non-small cell lung cancer was based on a multicenter, randomized, open-label conducted in 1052 chemonaive patients with Stage IIIb/IV non-small cell lung cancer. The trial was designed to compare Abraxane in combination with carboplatin to paclitaxel injection in combination with carboplatin as first-line treatment. Abraxane was administered as an intravenous infusion over 30 minutes at a dose of 100 mg/m2 on Days 1, 8, and 15 of each 21-day cycle. Paclitaxel injection was administered as an intravenous infusion over 3 hours at a dose of 200 mg/m2, following premedication. In both treatment arms carboplatin at a dose of AUC = 6 mg min/mL was administered intravenously on Day 1 of each 21-day cycle after completion of Abraxane/paclitaxel infusion. Treatment was administered until disease progression or development of an unacceptable toxicity. The primary efficacy outcome was overall response rate. Subjects in the Abraxane/carboplatin arm had a statistically significantly higher overall response rate compared to those in the paclitaxel injection/carboplatin arm (33% versus 25%). There was no statistically significant difference in overall survival between the two study arms.

    Side Effects

    Adverse events associated with the use of Abraxane when used in combination with carboplatin for non-small cell lung cancer may include, but are not limited to, the following:

    • anemia
    • neutropenia
    • thrombocytopenia
    • alopecia
    • peripheral neuropathy
    • nausea
    • fatigue

    Mechanism of Action

    Abraxane is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays (or bundles) of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.

    Literature References

    Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Jun 10;30(17):2055-62

    Additional Information

    For additional information regarding Abraxane or non-small cell lung cancer, please visit the Abraxane web page.

    Approval Date: 2012-10-01
    Company Name: Celgene
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • SurveywBlueBackground-360x240.png

      Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

    • TrendsInsights2023-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Two

    • TimeMoneyEffort-360x240.png

      Time is Money and So Is Effort, Budgeting Experts Say

    • TrendsInsights2023A-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Three

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing